Citations

Showing 10 of 108083 citations.

Two‐Year Outcomes With a Next‐Generation Left Atrial Appendage Device: Final Results of the PINNACLE FLX Trial
Doshi, Shephal K. , Kar, Saibal , Sadhu, Ashish, Horton, Rodney , Osorio, José , Ellis, Christopher R. , Stone, James, Shah, Manish H. , Dukkipati, Srinivas R. , Adler, Stuart W., Kim, Jamie , Wazni, Oussama M. , Holmes, David R. , Shipley, Robert D., Christen, Thomas, Allocco, Dominic J. , Buchbinder, Maurice , Chinitz, Larry A. , Desai, Amish J., Dukkipatti, Srinivas R., Ellis, Christopher, Gibson, Douglas , Huber, Kenneth, Khairallah, Farhat, Koneru, Jayanthi N. , Mahoney, Paul G. , Mansour, Moussa , Mark, George E., Nicholson, William , REISS, J. A., Shehata, Michael , Swarup, Vijendra, Huber, Kurt , Téllez-Plaza, María , Ellis, Christopher , Shah, Manish , Nair, Devi G , Wazni, Oussama , Price, Matthew J , Holmes, David R , Reddy, Vivek Y , Kar, Saibal , Huber, Kurt , Price, Matthew J. , Reddy, Vivek Y. , DeLurgio, David B. , Ellis, Christopher, Huber, Kenneth, Mahoney, Paul, O’Neill, William W. , Reiss, James, Saliba, Walid I.

Mayo Clinic

Journal of the American Heart Association | February 21, 2023 | Volume: 12 | Issue: 4 | Pages: No page available

10.1161/jaha.122.026295 | PMID 36789852 Get It

Background The PINNACLE FLX (Protection Against Embolism for Non‐valvular AF [Atrial Fibrillation] Patients: Investigational Device Evaluation of the Watchman FLX LAA [Left Atrial Appendage] Closure Technology) trial evaluated the safety and efficacy of a next‐generation left atrial appendage closure device (WATCHMAN FLX; Boston Scientific, Marlborough, MA). At 1 year, the study met the primary end points of safety and anatomical efficacy/appendage closure. This final report of the PINNACLE FLX trial includes the prespecified secondary end point of ischemic stroke or systemic embolism at 2 years, also making it the first report of 2‐year outcomes with this next‐generation left atrial appendage closure device. Methods and Results Patients with nonvalvular atrial fibrillation with CHA 2 DS 2 ‐VASc score ≥2 (men) or ≥3 (women), with an appropriate rationale for left atrial appendage closure, were enrolled to receive the left atrial appendage closure device at 29 US centers. Adverse events were assessed by an independent clinical events committee, and imaging was assessed by independent core laboratories. Among 395 implanted patients (36% women; mean age, 74 years; CHA 2 DS 2 ‐VASc, 4.2±1.5), the secondary efficacy end point of 2‐year ischemic stroke or systemic embolism was met, with an absolute rate of 3.4% (annualized rate, 1.7%) and an upper 1‐sided 95% confidence bound of 5.3%, which was superior to the 8.7% performance goal. Two‐year rates of adverse events were as follows: 9.3% all‐cause mortality, 5.5% cardiovascular death, 3.4% all stroke, and 10.1% major bleeding (Bleeding Academic Research Consortium 3 or 5). There were no additional systemic embolisms, device embolizations, pericardial effusions, or symptomatic device‐related thrombi after 1 year. Conclusions The secondary end point of 2‐year stroke or systemic embolism was met at 3.4%. In these final results of the PINNACLE FLX trial, the next‐generation WATCHMAN FLX device demonstrated favorable safety and efficacy outcomes.
Association of African Ancestry–Specific APOE Missense Variant R145C With Risk of Alzheimer Disease
Guen, Yann Le , Raulin, Ana‐Caroline , Belloy, Michaël E. , Eger, Sarah J. , Kennedy, Gabriel , Kuchenbecker, Lindsey A. , O’Leary, Justin , Panizzon, Matthew S. , Hauger, Richard L. , Gaziano, J. Michael , Bu, Guojun , Thornton, Timothy A. , He, Zihuai , Greicius, Michael D. , Kuchenbecker, Lindsey, O'Leary, Justin P, Bu, Guojun , Raulin, Ana-Caroline , Le Guen, Yann , Belloy, Michael E , Logue, Mark W. , Sherva, Richard , Chen, Shen‐Hsing Annabel , Zhang, Rui , Merritt, Victoria C. , Hauger, Richard L. , Farrer, Lindsay A. , Napolioni, Valerio

Mayo Clinic

JAMA | February 21, 2023 | Volume: 329 | Issue: 7 | Pages: 551

10.1001/jama.2023.0268 | PMID 36809323 Get It

Importance Numerous studies have established the association of the common APOE ε2 and APOE ε4 alleles with Alzheimer disease (AD) risk across ancestries. Studies of the interaction of these alleles with other amino acid changes on APOE in non-European ancestries are lacking and may improve ancestry-specific risk prediction. Objective To determine whether APOE amino acid changes specific to individuals of African ancestry modulate AD risk. Design, Setting, and Participants Case-control study including 31 929 participants and using a sequenced discovery sample (Alzheimer Disease Sequencing Project; stage 1) followed by 2 microarray imputed data sets derived from the Alzheimer Disease Genetic Consortium (stage 2, internal replication) and the Million Veteran Program (stage 3, external validation). This study combined case-control, family-based, population-based, and longitudinal AD cohorts, which recruited participants (1991-2022) in primarily US-based studies with 1 US/Nigerian study. Across all stages, individuals included in this study were of African ancestry. Exposures Two APOE missense variants (R145C and R150H) were assessed, stratified by APOE genotype. Main Outcomes and Measures The primary outcome was AD case-control status, and secondary outcomes included age at AD onset. Results Stage 1 included 2888 cases (median age, 77 [IQR, 71-83] years; 31.3% male) and 4957 controls (median age, 77 [IQR, 71-83] years; 28.0% male). In stage 2, across multiple cohorts, 1201 cases (median age, 75 [IQR, 69-81] years; 30.8% male) and 2744 controls (median age, 80 [IQR, 75-84] years; 31.4% male) were included. In stage 3, 733 cases (median age, 79.4 [IQR, 73.8-86.5] years; 97.0% male) and 19 406 controls (median age, 71.9 [IQR, 68.4-75.8] years; 94.5% male) were included. In ε3/ε4-stratified analyses of stage 1, R145C was present in 52 individuals with AD (4.8%) and 19 controls (1.5%); R145C was associated with an increased risk of AD (odds ratio [OR], 3.01; 95% CI, 1.87-4.85; P = 6.0 × 10 −6 ) and was associated with a reported younger age at AD onset (β, −5.87 years; 95% CI, −8.35 to −3.4 years; P = 3.4 × 10 −6 ). Association with increased AD risk was replicated in stage 2 (R145C was present in 23 individuals with AD [4.7%] and 21 controls [2.7%]; OR, 2.20; 95% CI, 1.04-4.65; P = .04) and was concordant in stage 3 (R145C was present in 11 individuals with AD [3.8%] and 149 controls [2.7%]; OR, 1.90; 95% CI, 0.99-3.64; P = .051). Association with earlier AD onset was replicated in stage 2 (β, −5.23 years; 95% CI, −9.58 to −0.87 years; P = .02) and stage 3 (β, −10.15 years; 95% CI, −15.66 to −4.64 years; P = 4.0 × 10 −4 ). No significant associations were observed in other APOE strata for R145C or in any APOE strata for R150H. Conclusions and Relevance In this exploratory analysis, the APOE ε3[R145C] missense variant was associated with an increased risk of AD among individuals of African ancestry with the ε3/ε4 genotype. With additional external validation, these findings may inform AD genetic risk assessment in individuals of African ancestry.
Lidocaine for Neuropathic Cancer Pain (LiCPain): study protocol for a mixed-methods pilot study
Lee, Jessica , Currow, David C. , Phillips, Jane , McLachlan, Andrew J. , Ritchie, Megan, Fazekas, Belinda, Aggarwal, Rajesh , Seah, Davinia , Chye, Richard , Noble, Beverly, Aggarwal, Ghauri, George, Rachel, Kow, Marian, Ayoub, Chadi , Linton, Anthony , Sanderson, Christine , Mittal, Dipti, Rao, Angela , Prael, Grace , Urban, Katalin, Vandersman, Priyanka , Agar, Meera , McCaffrey, Nikki , Lovell, Melanie R , Brown, Linda , Sheehan, Caitlin

Mayo Clinic

BMJ Open | February 21, 2023 | Volume: 13 | Issue: 2 | Pages: e066125

10.1136/bmjopen-2022-066125 | PMID 36810169 Get It

Introduction Many patients experience unrelieved neuropathic cancer-related pain. Most current analgesic therapies have psychoactive side effects, lack efficacy data for this indication and have potential medication-related harms. The local anaesthetic lidocaine (lignocaine) has the potential to help manage neuropathic cancer-related pain when administered as an extended, continuous subcutaneous infusion. Data support lidocaine as a promising, safe agent in this setting, warranting further evaluation in robust, randomised controlled trials. This protocol describes the design of a pilot study to evaluate this intervention and explains the pharmacokinetic, efficacy and adverse effects evidence informing the design. Methods and analysis A mixed-methods pilot study will determine the feasibility of an international first, definitive phase III trial to evaluate the efficacy and safety of an extended continuous subcutaneous infusion of lidocaine for neuropathic cancer-related pain. This study will comprise: a phase II double-blind randomised controlled parallel-group pilot of subcutaneous infusion of lidocaine hydrochloride 10% w/v (3000 mg/30 mL) or placebo (sodium chloride 0.9%) over 72 hours for neuropathic cancer-related pain, a pharmacokinetic substudy and a qualitative substudy of patients’ and carers’ experiences. The pilot study will provide important safety data and help inform the methodology of a definitive trial, including testing proposed recruitment strategy, randomisation, outcome measures and patients’ acceptability of the methodology, as well as providing a signal of whether this area should be further investigated. Ethics and dissemination Participant safety is paramount and standardised assessments for adverse effects are built into the trial protocol. Findings will be published in a peer-reviewed journal and presented at conferences. This study will be considered suitable to progress to a phase III study if there is a completion rate where the CI includes 80% and excludes 60%. The protocol and Patient Information and Consent Form have been approved by Sydney Local Health District (Concord) Human Research Ethics Committee 2019/ETH07984 and University of Technology Sydney ETH17-1820. Trial registration number ANZCTR ACTRN12617000747325.
Comparison between mono‐tacrolimus and mono‐glucocorticoid in the treatment of myasthenia gravis
Fan, Zhirong , Lei, Lin, Su, Shengyao , Zhang, Shu , Xie, Nairong , Li, Ling , Di, Li , Wang, Min , Xu, Min , Shen, Xin‐Ming , Da, Yuwei , Shen, Xin-Ming , Da, Yuwei , Lü, Yan , Di, Li

Mayo Clinic

Annals of Clinical and Translational Neurology | February 21, 2023 | Volume: 10 | Issue: 4 | Pages: 589-598

10.1002/acn3.51746 | PMID 36808840 Get It

AbstractObjectiveUse of tacrolimus in mild to moderate myasthenia gravis (MG) is generally limited to glucocorticoid‐refractory cases; the advantage of mono‐tacrolimus over mono‐glucocorticoids is unknown.MethodsWe included mild to moderate MG patients treated with mono‐tacrolimus (mono‐TAC) or mono‐glucocorticoids (mono‐GC). The correlation between the immunotherapy options and the treatment efficacy and side effects were examined in 1:1 propensity‐score matching. The main outcome was time to minimal manifestations status or better (MMS or better). Secondary outcomes include time to relapse, the mean changes in Myasthenia Gravis‐specific Activities of Daily Living (MG‐ADL) scores and the rate of adverse events.ResultsBaseline characteristics showed no difference between matched groups (49 matched pairs). There were no differences in median time to MMS or better between the mono‐TAC group and mono‐GC group (5.1 vs. 2.8 months: unadjusted hazard ratio [HR], 0.73; 95% CI, 0.46–1.16; p = 0.180), as well as in median time to relapse (data unavailable for the mono‐TAC group since 44 of 49 [89.8%] participants remained in MMS or better; 39.7 months in mono‐GC group: unadjusted HR, 0.67; 95% CI, 0.23–1.97; p = 0.464). Changes in MG‐ADL scores between the two groups were similar (mean differences, 0.3; 95% CI, −0.4 to 1.0; p = 0.462). The rate of adverse events was lower in the mono‐TAC group compared to the mono‐GC group (24.5% vs. 55.1%, p = 0.002).InterpretationMono‐tacrolimus performs superior tolerability with non‐inferior efficacy compared to mono‐glucocorticoids in mild to moderate myasthenia gravis patients who refuse or have a contraindication to glucocorticoids.
Racial, Ethnic, and Socioeconomic Inequities in Access to Left Atrial Appendage Occlusion
Reddy, Kriyana P. , Eberly, Lauren A. , Halaby, Rim , Julien, Howard , Khatana, Sameed Ahmed M. , Dayoub, Elias J. , Coylewright, Megan , Alkhouli, Mohamad , Fiorilli, Paul N. , Kobayashi, Taisei , Santangeli, Pasquale , Giri, Jay , Nathan, Ashwin S. , Kobayashi, Taisei J , Santangeli, Pasquale , Herrmann, Howard C , Giri, Jay , Groeneveld, Peter W , Fanaroff, Alexander C , Nathan, Ashwin S , Alkhouli, Mohamad , Goldberg, David M. , Herrmann, Howard C. , Fanaroff, Alexander C.

Mayo Clinic

Journal of the American Heart Association | February 21, 2023 | Volume: 12 | Issue: 5 | Pages: No page available

10.1161/jaha.122.028032 | PMID 36802837 Get It

Background Inequitable access to high‐technology therapeutics may perpetuate inequities in care. We examined the characteristics of US hospitals that did and did not establish left atrial appendage occlusion (LAAO) programs, the patient populations those hospitals served, and the associations between zip code–level racial, ethnic, and socioeconomic composition and rates of LAAO among Medicare beneficiaries living within large metropolitan areas with LAAO programs. Methods and Results We conducted cross‐sectional analyses of Medicare fee‐for‐service claims for beneficiaries aged 66 years or older between 2016 and 2019. We identified hospitals establishing LAAO programs during the study period. We used generalized linear mixed models to measure the association between zip code–level racial, ethnic, and socioeconomic composition and age‐adjusted rates of LAAO in the most populous 25 metropolitan areas with LAAO sites. During the study period, 507 candidate hospitals started LAAO programs, and 745 candidate hospitals did not. Most new LAAO programs opened in metropolitan areas (97.4%). Compared with non‐LAAO centers, LAAO centers treated patients with higher median household incomes (difference of $913 [95% CI, $197–$1629], P =0.01). Zip code–level rates of LAAO procedures per 100 000 Medicare beneficiaries in large metropolitan areas were 0.34% (95% CI, 0.33%–0.35%) lower for each $1000 zip code–level decrease in median household income. After adjustment for socioeconomic markers, age, and clinical comorbidities, LAAO rates were lower in zip codes with higher proportions of Black or Hispanic patients. Conclusions Growth in LAAO programs in the United States had been concentrated in metropolitan areas. LAAO centers treated wealthier patient populations in hospitals without LAAO programs. Within major metropolitan areas with LAAO programs, zip codes with higher proportions of Black and Hispanic patients and more patients experiencing socioeconomic disadvantage had lower age‐adjusted rates of LAAO. Thus, geographic proximity alone may not ensure equitable access to LAAO. Unequal access to LAAO may reflect disparities in referral patterns, rates of diagnosis, and preferences for using novel therapies experienced by racial and ethnic minority groups and patients experiencing socioeconomic disadvantage.
Serious Illness Communication Skills Training for Emergency Physicians and Advanced Practice Providers: A Multi-Method Assessment of the Reach and Effectiveness of the Intervention
Kaur, Regina, Zhao, Nicole, Siman, Nina , DrPH, Keith Goldfeld, Emlet, Lillian L. , Yamarik, Rebecca , Investigators, The PRIM-ER, Ginsburg, Alexander D, Adeyemi, Oluwaseun , Ginsburg, Alexander , Cuthel, Allison M. , DrPH, Keith Goldfeld, DiMaggio, Charles J. , Bouillon‐Minois, Jean‐Baptiste , Chodosh, Joshua , Grudzen, Corita R.

Mayo Clinic

No container title available | February 21, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2561749/v1 | PMID 36865121 Get It

AbstractBackground EM Talk is a communication skills training program designed to improve emergency providers’ serious illness conversational skills. Using the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework, this study aims to assess the reach of EM Talk and its effectiveness. Methods EM Talk is one of the components of Primary Palliative Care for Emergency Medicine (EM) intervention. It consisted of one 4-hour training session during which professional actors used role-plays and active learning to train providers to deliver serious/bad news, express empathy, explore patients’ goals, and formulate care plans. After the training, emergency providers filled out an optional post-intervention survey, which included course reflections. Using a multi-method analytical approach, we analyzed the reach of the intervention quantitatively and the effectiveness of the intervention qualitatively using conceptual content analysis of open-ended responses. Results A total of 879 out of 1,029 (85%) EM providers across 33 emergency departments completed the EM Talk training, with the training rate ranging from 63–100%. From the 326 reflections, we identified meaning units across the thematic domains of improved knowledge, attitude, and practice. The main subthemes across the three domains were the acquisition of discussion tips and tricks, improved attitude toward engaging qualifying patients in serious illness (SI) conversations, and commitment to using these learned skills in clinical practice. Conclusion Effectively engaging qualifying patients in serious illness conversations requires appropriate communication skills. EM Talk has the potential to improve emergency providers’ knowledge, attitude, and practice of SI communication skills.Trial registration:NCT03424109
Diffuse Pulmonary Meningotheliomatosis: Clinic-Pathologic Entity or Indolent Metastasis from Meningioma (or Both)?
Melocchi, Laura , Rossi, Giulio , Valli, Mirca, Mondoni, Michele , Lazzari-Agli, Luigi, Santandrea, Giacomo , Baldovini, Chiara , Colby, Thomas V. , Mondoni, Michele , Santandrea, Giacomo , Mengoli, Maria Cecilia , Davoli, Fabio

Mayo Clinic

Diagnostics | February 21, 2023 | Volume: 13 | Issue: 4 | Pages: 802

10.3390/diagnostics13040802 | PMID 36832290 Get It

Pulmonary minute meningothelial-like nodules (MMNs) are common incidental findings in surgical specimens, consisting of tiny proliferation (usually no larger than 5–6 mm) of bland-looking meningothelial cells showing a perivenular and interstitial distribution, sharing morphologic, ultrastructural, and immunohistochemical profiles with meningiomas. The identification of multiple bilateral MMNs leading to an interstitial lung disease characterized by diffuse and micronodular/miliariform patterns radiologically allows the diagnosis of diffuse pulmonary meningotheliomatosis (DPM). Nevertheless, the lung is the most common site of metastatic primary intracranial meningioma, and differential diagnosis with DPM may be impossible without clinic–radiologic integration. Herein, we report four cases (three females; mean age, 57.5 years) fitting the criteria of DPM, all incidentally discovered and histologically evidenced on transbronchial biopsy (2) and surgical resection (2). All cases showed immunohistochemical expression of epithelial membrane antigen (EMA), progesterone receptor, and CD56. Notably, three of these patients had a proven or radiologically suspected intracranial meningioma; in two cases, it was discovered before, and in one case, after the diagnosis of DPM. An extensive literature review (44 patients with DPM) revealed similar cases with imaging studies excluding intracranial meningioma in only 9% (4 of 44 cases studied). The diagnosis of DPM requires close correlation with the clinic–radiologic data since a subset of cases coexist with or follow a previously diagnosed intracranial meningioma and, thus, may represent incidental and indolent metastatic deposits of meningioma.
What Is the Role of Norepinephrine in Cerebellar Modulation and Stress-Induced Episodic Ataxia?
Benarroch, Eduardo E.

Mayo Clinic

Neurology | February 20, 2023 | Volume: 100 | Issue: 8 | Pages: 383-386

10.1212/wnl.0000000000206882 | PMID 36806456 Get It

Clinical Reasoning: New-Onset Diplopia and Headache in a Patient With Metastatic Breast Cancer
Rizzo, Skylar A. , Trejo‐Lopez, Jorge , Toledano, Michel , Trejo-Lopez, Jorge A, Chia, Nicholas H , Flanagan, Eoin P. , Chia, Nicholas

Mayo Clinic

Neurology | February 20, 2023 | Volume: 100 | Issue: 19 | Pages: 927-931

10.1212/wnl.0000000000206856 | PMID 36805434 Get It

Whom to Screen and How to Screen for Obstructive Sleep Apnea in the Cardiology Clinic
Somers, Virend K. , Mansukhani, Meghna P , Somers, Virend K. , Mansukhani, Meghna P.

Mayo Clinic

Circulation | February 20, 2023 | Volume: 147 | Issue: 8 | Pages: 621-623

10.1161/circulationaha.122.060899 | PMID 36802885 Get It